The Cancer Market Outlook to 201615 Jul 2011 • by Natalie Aster
The global cancer market is becoming increasingly competitive, with two therapeutic classes, namely antineoplastics and cytostatic hormonal treatments, dominating this sector. The report “The Cancer Market Outlook to 2016” by Business Insights presents leading products, developments, and market forecasts for each of these classes. Eighteen recently launched/late-stage pipeline products are discussed in detail.
The report allows you to:
- Understand how recent events are affecting the performance of major products, and how companies are confronting competitive market changes;
- Compare the franchises of the leading companies in the cancer market, and understand how the market share of these companies will change;
- Assess key pipeline products by indication, ongoing trials, recent product launches, and key developments in R&D;
- Identify the challenges faced by leading players, and understand how recent events will impact the performance of leading products;
- Gain insights into the forecasts of the leading marketed and pipeline products through to 2016.
Your key questions answered:
- What will be the major growth indications and the accompanying growth drivers in the cancer market over the next 6 years?
- Which were the leading players in the cancer market in 2010?
- Which products will be the future growth drivers for the cancer health market?
- Which therapeutic categories are forecast to have the highest levels of commercial potential over the period 2010–16?
- Which companies are best positioned to succeed in the cancer market over the period 2010–16?
Published: June 2011
Price: US$ 3,835.00
The key factor for growth of the cancer therapy market is the expansion of target indications. Most of the blockbuster drugs were launched for a narrow indication, but later gained approval for a wider range of indications.
Regardless of indication, the key challenge in ensuring the commercial success of pipeline drugs is to ascertain their integration into current treatment regimens either in combination with existing therapies or by demonstrating significant superiority over current treatments.
Pricing risk remains the key investment concern in cancer. Moreover, the level of scrutiny by payers regarding the cost-effectiveness of cancer treatments has intensified in recent years.
To order the report or ask for sample pages contact firstname.lastname@example.org
Tel: +44 208 144 6009
Fax: +44 207 900 3970